HDAC9 and amyotrophic lateral sclerosis: Using histone deacetylase (HDAC) inhibitors in the FUS-ALS models can influence cytoplasmic localization of FUS, promote the acetylation of FUS RNA binding domain (RRM) and change its interaction with RNA.